Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. - Gordon, Kenneth B; Foley, Peter; Krueger, James G; Pinter, Andreas; Reich, Kristian; Vender, Ronald; Vanvoorden, Veerle; Madden, Cynthia; White, Katy; Cioffi, Christopher; Blauvelt, Andrew (Lancet, 2021)